



Rohit Gupta

Research Engineer, Pathology Sponsored Projects

Bio

EDUCATION AND CERTIFICATIONS

- PhD, University of California, Merced (2019)

Publications

PUBLICATIONS

- **Longitudinal multimodal profiling of IDH-wildtype glioblastoma reveals the molecular evolution and cellular phenotypes underlying prognostically different treatment responses**
Lucas, C., Al-Adli, N., Young, J., Gupta, R., Morshed, R., Wu, J., Ravindranathan, A., Shai, A., Oberheim Bush, N., Taylor, J., De Groot, J., Villanueva-Meyer, J., Pekmezci, et al
AMER ASSOC CANCER RESEARCH.2026: A061
- **The single cell landscape of NF1-associated gliomas pre- and post-treatment and comparison to their sporadic counterparts**
Gupta, R., Ravindranathan, A., Wu, J., Lucas, C., Shai, A., Nazarian, J., Campen, C., Partap, S., Omuro, A., Gephart, M., Lim, M., Butowski, N., Berger, et al
OXFORD UNIV PRESS INC.2025: v262
- **DNA methylation-based classification of kidney neoplasms. *Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc***
Papanicolau-Sengos, A., Singh, O., Park, K., Snuderl, M., Tretiakova, M., Merino, M., Stohr, B., Simko, J., Deng, F. M., Chan, E., Wu, J., Barreto, J., Gupta, et al
2025: 100884
- **Tumor heterogeneity underlies clinical outcome and MEK inhibitor response in somatic NF1-mutant glioblastoma *JCI INSIGHT***
Pan, S., Mirchia, K., Payne, E., Liu, S., Al-Adli, N., Peeran, Z., Shukla, P., Young, J. S., Gupta, R., Wu, J., Pak, J., Ozawa, T., Na, et al
2025; 10 (18)
- **Longitudinal multimodal profiling of IDH-wildtype glioblastoma reveals the molecular evolution and cellular phenotypes underlying prognostically different treatment responses. *Neuro-oncology***
Lucas, C. G., Al-Adli, N. N., Young, J. S., Gupta, R., Morshed, R. A., Wu, J., Ravindranathan, A., Shai, A., Oberheim Bush, N. A., Taylor, J. W., de Groot, J., Villanueva-Meyer, J. E., Pekmezci, et al
2025; 27 (1): 89-105
- **DNA MUTATION SEQUENCING AND METHYLATION ANALYSIS OF SOMATICNF1 MUTANT IDH-WILDTYPE GLIOBLASTOMA IDENTIFIES THREE EPIGENETIC GROUPS ANDCDKN2A/B LOSS AS A NEGATIVE PROGNOSTIC BIOMARKER**
Mirchia, K., Pan, S., Payne, E., Liu, J., Peeran, Z., Shukla, P., Young, J., Gupta, R., Wu, J., Pak, J., Seo, K., Ozawa, T., Na, et al
OXFORD UNIV PRESS INC.2024
- **SINGLE-CELL RNA (SCRNA) SEQUENCING OF PAIRED PRIMARY AND RECURRENT ATYPICAL TERATOID/RHABDOID TUMORS (AT/RT) REVEALED MOLECULAR DIFFERENCES AND THERAPY-RESISTANT PRIMARY TUMOR CELLS**
Altendorf, L., Roy, R., de Faria, F. W., Hack, K., Koch, A., Schuhmann, M. U., Hauser, P., Johann, P. D., Hasselblatt, M., Kerl, K., Fruehwald, M. C., Schueller, U.

OXFORD UNIV PRESS INC.2024

- **"De novo replication repair deficient glioblastoma, IDH-wildtype" is a distinct glioblastoma subtype in adults that may benefit from immune checkpoint blockade.** *Acta neuropathologica*
Hadad, S., Gupta, R., Oberheim Bush, N. A., Taylor, J. W., Villanueva-Meyer, J. E., Young, J. S., Wu, J., Ravindranathan, A., Zhang, Y., Warriar, G., McCoy, L., Shai, A., Pekmezci, et al
2023; 147 (1): 3
- **Novel SOX10 indel mutations drive schwannomas through impaired transactivation of myelination gene programs.** *Neuro-oncology*
Williams, E. A., Ravindranathan, A., Gupta, R., Stevers, N. O., Suwala, A. K., Hong, C., Kim, S., Yuan, J. B., Wu, J., Barreto, J., Lucas, C. G., Chan, E., Pekmezci, et al
2023; 25 (12): 2221-2236
- **Somatic mosaic SOX10 indel mutations underlie a form of segmental schwannomatosis.** *Acta neuropathologica*
Terry, M., Gupta, R., Ravindranathan, A., Wu, J., Chan, E., Bollen, A. W., Chang, S. M., Berger, M. S., Jacques, L., Solomon, D. A.
2023; 146 (6): 857-860
- **Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1.** *Acta neuropathologica*
Lucas, C. G., Sloan, E. A., Gupta, R., Wu, J., Pratt, D., Vasudevan, H. N., Ravindranathan, A., Barreto, J., Williams, E. A., Shai, A., Whipple, N. S., Bruggers, C. S., Maher, et al
2022; 144 (4): 747-765
- **Intracranial mesenchymal tumors with FET-CREB fusion are composed of at least two epigenetic subgroups distinct from meningioma and extracranial sarcomas.** *Brain pathology (Zurich, Switzerland)*
Sloan, E. A., Gupta, R., Koelsche, C., Chiang, J., Villanueva-Meyer, J. E., Alexandrescu, S., Eschbacher, J. M., Wang, W., Mafra, M., Ud Din, N., Carr-Boyd, E., Watson, M., Punsoni, et al
2022; 32 (4): e13037
- **EWSR1-BEND2 fusion defines an epigenetically distinct subtype of astroblastoma.** *Acta neuropathologica*
Lucas, C. G., Gupta, R., Wu, J., Shah, K., Ravindranathan, A., Barreto, J., Gener, M., Ginn, K. F., Prall, O. W., Xu, H., Kee, D., Ko, H. S., Yaqoob, et al
2022; 143 (1): 109-113
- **Tumor DNA requirements for accurate epigenetic-based classification of CNS neoplasia.** *Neuro-oncology*
Wu, J., Gupta, R., Barreto, J., Doo, P., Joseph, N. M., Lee, J. C., Perry, A., Chang, S. M., Berger, M. S., Solomon, D. A.
2021; 23 (10): 1798-1800
- **Low-grade glioneuronal tumors with FGFR2 fusion resolve into a single epigenetic group corresponding to 'Polymorphous low-grade neuroepithelial tumor of the young'.** *Acta neuropathologica*
Gupta, R., Lucas, C. G., Wu, J., Barreto, J., Shah, K., Simon, I. B., Casavilca-Zambrano, S., Brathwaite, C., Zhou, H., Caccamo, D., Gilani, A., Kleinschmidt-DeMasters, B. K., Lee, et al
2021; 142 (3): 595-599
- **The immunohistochemical, DNA methylation, and chromosomal copy number profile of cauda equina paraganglioma is distinct from extra-spinal paraganglioma.** *Acta neuropathologica*
Ramani, B., Gupta, R., Wu, J., Barreto, J., Bollen, A. W., Thian, T., Mummaneni, P. V., Ames, C., Clark, A., Oberheim Bush, N. A., Butowski, N., Phillips, D., King, et al
2020; 140 (6): 907-917
- **Comprehensive analysis of diverse low-grade neuroepithelial tumors with FGFR1 alterations reveals a distinct molecular signature of rosette-forming glioneuronal tumor.** *Acta neuropathologica communications*
Lucas, C. G., Gupta, R., Doo, P., Lee, J. C., Cadwell, C. R., Ramani, B., Hofmann, J. W., Sloan, E. A., Kleinschmidt-DeMasters, B. K., Lee, H. S., Wood, M. D., Grafe, M., Born, et al
2020; 8 (1): 151
- **Pediatric bithalamic gliomas have a distinct epigenetic signature and frequent EGFR exon 20 insertions resulting in potential sensitivity to targeted kinase inhibition.** *Acta neuropathologica*
Mondal, G., Lee, J. C., Ravindranathan, A., Villanueva-Meyer, J. E., Tran, Q. T., Allen, S. J., Barreto, J., Gupta, R., Doo, P., Van Ziffle, J., Onodera, C., Devine, P., Grenert, et al
2020; 139 (6): 1071-1088

- **Gliomas arising in the setting of Li-Fraumeni syndrome stratify into two molecular subgroups with divergent clinicopathologic features.** *Acta neuropathologica*
Sloan, E. A., Hiltz, S., Gupta, R., Cadwell, C., Ramani, B., Hofmann, J., Kline, C. N., Banerjee, A., Reddy, A., Oberheim Bush, N. A., Chang, S., Braunstein, S., Chang, et al
2020; 139 (5): 953-957
- **Isolation of PBMCs Using Vacutainer® Cellular Preparation Tubes** *Bio-protocol*
Puleo, A., Carroll, C., Maecker, H., Gupta, R.
2017; 7 (2)
- **Hypermutation of DPYD Deregulates Pyrimidine Metabolism and Promotes Malignant Progression.** *Molecular cancer research : MCR*
Edwards, L., Gupta, R., Filipp, F. V.
2016; 14 (2): 196-206
- **Cancer systems biology of TCGA SKCM: efficient detection of genomic drivers in melanoma.** *Scientific reports*
Guan, J., Gupta, R., Filipp, F. V.
2015; 5: 7857